Deborah Young, DPT Physical Therapist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1200 Brown St, Peekskill, NY 10566 Phone: 914-734-8903 Fax: 914-734-8551 |
Gabriela Rodriguez Physical Therapist Medicare: Medicare Enrolled Practice Location: 939 Central Ave, Peekskill, NY 10566 Phone: 914-488-5763 |
Laura Burkhalter Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 8 John Walsh Blvd Ste 406a, Peekskill, NY 10566 Phone: 914-631-9020 |
Mr. Kyle Mack, P.T. Physical Therapist - Orthopedic Medicare: Medicare Enrolled Practice Location: 150 Overlook Ave, Apt 1a, Peekskill, NY 10566 Phone: 914-484-8246 |
Dana Lynn Pinatello, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 910 Parkway Pl, Peekskill, NY 10566 Phone: 914-382-6346 Fax: 914-885-2961 |
Ms. Rebecca Belanger, MPT Physical Therapist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 130 Fields Ln, Peekskill, NY 10566 Phone: 914-980-6796 |
Nicole Bartosch, DPT Physical Therapist Medicare: May Accept Medicare Assignments Practice Location: 939 Central Ave, Peekskill, NY 10566 Phone: 914-488-5763 |
News Archive
ViVre Medical today launches Lifeguard30(TM), the newest life saving tool for consumers to arm themselves with information that may potentially save their life in an emergency.
EKF, announces results from a study involving EKF Molecular's PointMan™ DNA enrichment technology have been published in Clinical Cancer Research.
An earthquake has just shaken the Greek island. Damage is widespread and all conventional, terrestrial communications have been destroyed. The rescue operations have only one means at their disposal that has not been affected by the quake - a satellite which, from its altitude of 36 000 kilometres, can immediately link the locations involved in the catastrophe with the appropriate authorities.
Two studies a decade apart in England show fewer mental health inpatients are experiencing delayed discharge from hospital, although finding accommodation on discharge is a greater problem.
Takeda Pharmaceutical Company Limited ("Takeda") today announced that a Marketing Authorisation Application (MAA) has been submitted to The European Medicines Agency (EMA) for vedolizumab, an investigational, gut-selective humanized monoclonal antibody for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), the two most common types of inflammatory bowel disease (IBD).
› Verified 6 days ago